CA-MITOQ
13.4.2022 13:07:05 CEST | Business Wire | Press release
MitoQ Ltd. , a New Zealand-based cell health company that developed a world-first sub-cellular targeted antioxidant which directly combats cell stress, today announced a complete transformation of the brand with a fresh new design, updated visual language and sustainable packaging. MitoQ is the developer of the unique, next-generation cell health molecule with the same name, that is scientifically shown to penetrate deep within the cells to reduce cell stress. By supporting the body’s primary energy source – the mitochondria -- MitoQ is able to target cell stress and improve energy, increase exercise recovery and resilience and promote healthy aging. The patented, powerful cell technology and active ingredients in MitoQ will remain the same, but the rebrand elevates the company’s purpose, its differentiated position in the wider category and role as a pioneer of cell health with a new look and feel, including new packaging, visual communications and brand messaging.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220413005266/en/
“MitoQ is more than a supplement – it is biodesigned differently to be extraordinarily effective and safe, it’s backed by decades of independent global research and supported by clinical trials and hundreds of peer reviewed scientific publications,” said Mahara Inglis, chief executive officer of MitoQ. “Rebranding is one of the steps we are taking to raise awareness of the importance of cells for overall wellbeing and draw attention to our unique technology. All the elements in our new branding and packaging are designed to reflect the unique position we hold -- not only in the health and wellness space -- but in the emerging cellular health category which we have been pioneering for decades, and also the positive impact we make on our customers’ lives. MitoQ helps all individuals – whether they are managing a health condition, juggling busy days at work or as a parent, or those just wanting to age ‘better’ by reducing cell stress. We wanted our new brand to visually depict our proprietary science and appeal to all individuals who want to improve their health, starting at the smallest level: their cells. The new branding captures the essence of MitoQ’s purpose, unique mechanism of action and the positive user experience and we’re thrilled to introduce it to the world.”
The MitoQ rebrand was undertaken to revitalize the brand position, establish a clear point of differentiation in the category and ensure all packaging was sustainable to prevent inefficiencies that may contribute to environmental harm. To help inform the strategy and execution for the rebrand, MitoQ partnered with UK-based brand transformation consultancy, Born Ugly . Through a collaborative, agile process, Born Ugly was able to support MitoQ to more effectively define the brand’s identity, vision and purpose, including business and consumer insight generation, strategic plan development, brand definition, creation and design and brand activation. At the heart of the work was the shift of the brand’s purpose from supporting consumers to ‘power through life’ to ‘empower their purpose’ through products and experiences. The approach needed to overcome cultural differences and reasons for taking MitoQ in its key markets – primarily the U.S. and China. A unifying mindset was identified that could connect the different audiences rooted in a deep human truth that when people feel their best, they can have the most positive influence on those around them.
MitoQ’s new visual articulation was rooted in the idea that small changes can have a significant and positive ripple effect on overall health, life, and the broader community. The ‘power of small’ was the idea that influenced everything within MitoQ’s new brand, including cell-inspired packaging, imagery, illustration, animation, language, and a logo that articulates a cell universe optimized at the heart by MitoQ’s small molecule. Essentially the brand proposition is that small can be big.
“Today marks a significant milestone in the history and forward growth of our company. MitoQ is not only a reputable, innovative company pioneering new technology in the emerging cellular health category, but we are a supportive and loyal community of health-minded people who are committed to making a positive impact in the world around us,” said John Marshall, chief marketing officer at MitoQ. “This project was an intense and rewarding labor of love for the entire commercial organization. We are incredibly grateful to our strategic partners, external and internal advisors, the MitoQ team and the millions of global customers who helped provide thoughtful, invaluable feedback and perspective that led to the development of this refreshed, dynamic brand. We look forward to the commercial rollout and sharing this new brand experience with our customers across multiple global regions in the coming months.”
MitoQ is a multi-patented, advanced antioxidant molecule that delivers targeted support to the cells’ mitochondria. The mitochondria provide approximately 90% of the energy the human body needs to function. As a by-product of this energy production process, the mitochondria also produce free radicals, and with age (coupled with other external and environmental stressors), the body loses its natural resistance to diffuse them. MitoQ is bio-designed to be absorbed deep inside of the cells where it can neutralize free radicals to combat cell stress, resulting in more energy, faster exercise recovery, immune support, deeper focus and overall optimized health. For more information, visit www.mitoQ.com .
MitoQ is available globally via the brand website (www.mitoQ.com ), and Amazon.com.
About MitoQ
MitoQ is a New Zealand cellular health company that invented an advanced molecule which is clinically proven to target cells for better health. Created at the University of Otago in the 1990s, MitoQ’s unique ingredient is available in a range of cellular products designed to power the health and ambitions of every body. MitoQ’s potential benefits to health have been the subject of 12 clinical trials and over 600 independent published research papers by the likes of Harvard Medical School, UCLA and the University of Cambridge, and it holds 60 patents globally. For more information about the company and its products, visit www.mitoQ.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20220413005266/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Filippo Fagnani from Quanta System Receives the EAU Award for Significant Contribution to Endourology at ICE 202610.10.2026 18:09:00 CEST | Press release
Filippo Fagnani, Marketing & Scientific Director of Quanta System’s Surgical Division, has been honoured with the Award for Significant Contribution to Endourology at ICE26, the International Conference on Endourology organised by the EAU Endourology Section. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261010101303/en/ Filippo Fagnani receiving the prize with Olivier Traxer and Professor Bhaskar Somani. The recognition celebrates more than two decades of professional commitment to laser technology and a career built around a clear ambition: to translate the needs of urologists into increasingly precise, flexible and useful technologies, with the ultimate goal of supporting patient safety and better surgical outcomes. “I have always believed that technology should make the surgeon’s work more precise, more flexible and, most importantly, safer for the patient. My goal has never been to develop technology for its own sake,
Emdoor Information Marks 18 Years of Rugged Computing Excellence with Vertically Integrated Capabilities10.10.2026 12:30:00 CEST | Press release
As industrial automation, smart manufacturing, and field operations increasingly depend on mission-critical mobile computing, global demand for reliable rugged tablets, rugged laptops, and rugged handhelds continues to accelerate. Emdoor Information, a publicly listed company on China’s A-share main board since 2023 and an 18-year veteran in rugged computing, has established itself as a rugged computing solutions provider for industrial customers worldwide. Founded in 2008, the company delivers sustained growth, world-class manufacturing, resilient supply chains, full-stack R&D, and comprehensive lifecycle services. Its rugged computing products and industrial customers now span North America, Latin America, Europe, and Asia-Pacific, serving sectors such as public utilities, intelligent manufacturing, warehouse management, transportation, energy industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261010564561/en/ Rugged
Vertex to Present New Data on ALYFTREK® at the North American Cystic Fibrosis Conference9.10.2026 19:15:00 CEST | Press release
- Data on ALYFTREK in children ages 2 to 5 years demonstrate recovery of pancreatic function in some children –- Additional abstracts on clinical and real-world evidence on CFTR modulators also presented - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced new interim data from the ALYFTREK® (vanzacaftor/tezacaftor/deutivacaftor) 2 to 5 years old open-label extension study, highlighting recovery of exocrine pancreatic function in some children in that age group, allowing those children to discontinue pancreatic enzyme replacement therapy (PERT). Pancreatic exocrine insufficiency in children with cystic fibrosis (CF) was previously believed to be irreversible. These data were presented at the North American Cystic Fibrosis Conference (NACFC). “The data presented at NACFC underscore the safety and efficacy of our CF medicines in the real world and in clinical trials in younger age groups. The data from the Phase 3 open-label study in 2 to 5 year olds evaluating exocrine p
Andersen Consulting udvider med TalentSmartEQ for at fremme lederskab og virksomhedstransformation9.10.2026 18:48:00 CEST | Pressemeddelelse
Andersen Consulting styrker sine kompetencer inden for humankapital gennem en samarbejdsaftale med TalentSmartEQ, en San Diego-baseret virksomhed, der har fokus på at skabe praktiske, engagerende og handlingsorienterede læringsoplevelser med udgangspunkt i emotionel intelligens (EQ) og lederudvikling. I mere end to årtier har TalentSmartEQ arbejdet sammen med organisationer verden over med henblik på at udvikle ledelseskompetencer ved hjælp af emotionel intelligens og dermed styrke medarbejderengagement, teamwork og de samlede resultater. Virksomheden kombinerer forskningsbaserede metoder med praktiske læringsforløb, vurderinger, coaching og skræddersyede programmer, der skal omsætte opbygningen af emotionel intelligens til vedvarende ændringer i adfærden på arbejdspladsen. Som førende aktør i branchen samarbejder TalentSmartEQ med organisationer lige fra Fortune 500-virksomheder til offentlige myndigheder og privatejede virksomheder. "Organisationer stiller stadig større krav til dere
Verdant Rock Receives A (low) Financial Strength Rating from Morningstar DBRS, Adding a Second International Investment-Grade Assessment9.10.2026 16:00:00 CEST | Press release
Verdant Rock now holds Financial Strength Ratings from both Fitch Ratings and Morningstar DBRS, providing counterparties with dual-agency confirmation and reinforcing the security architecture behind each financial guarantee Verdant Rock Limited, a Bermuda Monetary Authority-regulated Class 3B insurance company, has received an A (low) Financial Strength Rating from Morningstar DBRS. The rating reflects Verdant Rock’s financial strength and its capacity to meet policyholder obligations as an investment-grade financial guarantor for Emerging Markets credit. Morningstar DBRS is a global credit rating agency with coverage across North America, Europe, Asia, and Latin America. Its assessment of Verdant Rock reflects the company’s strong projected earnings ability, robust risk profile, sound liquidity, and good capitalization. Morningstar DBRS also assigned an A (low) Issuer Rating to Verdant Rock. The rating follows Verdant Rock’s BBB+ Long-Term Insurer Financial Strength Rating with a Sta
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
